Stocktoria
Evommune, Inc. EVMN
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2025-11-06
Evommune, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $13.0M | $7.0M |
| R&D expense | $74.0M | $64.2M |
| Operating income | -$81.1M | -$70.0M |
| Income tax | $0 | $0 |
| Net income | -$68.9M | -$66.8M |
| EPS (diluted) | $-11.22 | $-45.29 |
| Operating cash flow | -$76.4M | -$58.2M |
| Free cash flow | -$76.7M | -$58.3M |
| Cash & equivalents | $44.1M | $16.3M |
| Total assets | $224.9M | $76.1M |
| Total liabilities | $19.4M | $28.5M |
| Shareholders' equity | $205.6M | -$144.2M |
Source: SEC EDGAR filings · CIK 0002044725 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.